Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.30 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2105143 | 0.79 | MEN1 (0.33) | — | |
| SCHEMBL18833426 | 0.78 | KDM4E (0.39) | PTPN5 | |
| SCHEMBL28060320 | 0.78 | KDM4E (0.39) | PTPN5 | |
| SCHEMBL28026085 | 0.77 | RORC (0.30) | RORC | |
| SCHEMBL1119411 | 0.77 | — | — | |
| SCHEMBL17707975 | 0.77 | ACHE (0.41) | P2RX3PTPN5 | |
| SCHEMBL17134126 | 0.76 | ALDH1A3 (0.30) | — | |
| SCHEMBL11238 | 0.75 | TDP1 (0.43) | — | |
| SCHEMBL30361331 | 0.75 | CYP3A4 (0.38) | RORC | |
| SCHEMBL9856281 | 0.75 | ESR2 (0.45) | RORCPTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | claimed |
| US-8809384-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | claimed |
| US-8703807-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120245191-A1 | NEW AZASPIRODECANONE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-09-27 | — | — | US | claimed |
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-09-20 | — | — | US | claimed |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | US | claimed |
| CN-103068826-B | Nitrogen heterocyclic | 霍夫曼-拉罗奇有限公司 | 2016-08-31 | — | — | CN | disclosed |
| EP-2688881-B1 | NEW AZASPIRODECANONE COMPOUNDS AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2016-02-10 | — | — | EP | disclosed |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-05-28 | — | — | US | disclosed |
| US-8809384-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8703807-B2 | Azaspirodecanone compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140005400-A1 | NEW AZACYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2430023-B1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-09-20 | — | — | US | disclosed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-2430023-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | US | disclosed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010130665-A1 | AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005400-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | RORC 374/4885LIPE 1/4885P2RX3 1899/4885 |
| US-20120238594-A1 | AZASPIRODECANONE COMPOUNDS | CYP51A1, HSD17B7, NR5A1 | RORC 315/4885LIPE 4568/4885P2RX3 3472/4885 |
| US-20100292212-A1 | NEW AZACYCLIC DERIVATIVES | GPR119, LDLR, LPL | RORC 1454/4885LIPE 10/4885P2RX3 1722/4885 |
| US-20120041013-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | RORC 374/4885LIPE 1/4885P2RX3 1899/4885 |
| US-20120245191-A1 | NEW AZASPIRODECANONE COMPOUNDS | TYMS, CDK11A, CDKN1A | RORC 515/4885LIPE 4854/4885P2RX3 1898/4885 |
| US-20150148363-A1 | NEW AZACYCLIC COMPOUNDS | LIPE, GPR119, LIPC | RORC 374/4885LIPE 1/4885P2RX3 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.